<DOC>
	<DOCNO>NCT00578578</DOCNO>
	<brief_summary>To study anti-inflammatory effect marine omega-3 fatty acid , also know n-3 polyunsaturated fatty acid ( PUFA ) , propose randomize , double-blinded , prospective , single-center trial examine effect supplementary n-3 PUFA serum high sensitivity ( h ) CRP level . Inclusion Criteria Age &gt; 18 h CRP &gt; 3mg/L &lt; 10 mg/L Exclusion Criteria Active infection Systemic Inflammatory Disease Autoimmune disorder Systemic Lupus Erythematosus ( SLE ) Rheumatoid Arthritis ( RA ) Systemic Sclerosis ( Scleroderma ) Sjögren 's Syndrome Behçet 's Syndrome The Vasculitis Syndromes Including : Wegener 's granulomatosis Temporal arteritis ( Giant cell arteritis ) Takayasu 's arteritis Henoch-Schönlein purpura Predominantly cutaneous vasculitis ( hypersensitivity vasculitis ) Sarcoidosis Amyloidosis Currently warfarin Cr &gt; 2.0 Fish Allergy Pregnancy unwillingness use form birth control woman child-bearing age 8 week . We enroll 200 pt . Willoughby Hills Family Health Center 2 month period 100 pt . receive OMEGA-3 , 100 pt . receive placebo Drug take 8 week Pt . return Willoughby Hills 8 week follow-up hsCRP . A brief questionnaire complete nurse/pt , include vital sign baseline follow-up . Primary Outcome : hsCRP level 8 week treatment PUFA</brief_summary>
	<brief_title>Trial Study Effects Supplementary Omega-3 Serum C-Reactive Protein Levels</brief_title>
	<detailed_description>All patient give 8 week supply placebo study drug . The exact composition active drug placebo detail . The physician patient blind . Patients instruct take three capsule daily morning . Each capsule drug contain 450 mg eicosapentaenoic acid ( EPA ) , active component . Thus , three capsule daily result 1350 mg daily EPA . They ask return clinic 8 week therapy follow-up hsCRP . Patients : Healthy patient see primary care set Department Internal Medicine Cleveland Clinic Health System Willoughby satellite . Drug : Active Arm : 1000 mg Lemon flavor Capsules . Three capsule every morning . Fill 45 % Eicosapentaenoic Acid 10 % Docosahexaenoic Acid 10 % Combined total Docopentaneoic Acid Alfa-Linoleic Acid Natural Lemon Oil Rosemary Liquid Extract D-alpha Tocopherol Vitamin E ( 67.1 % W/W ) ( 1000IU/G ) Antioxidants , proprietary mix Shell Gelatin Glycerol Purified Water Lemon Oil Placebo Arm : Cornstarch Capsules provide Clinical Encapsulation service . Three capsule every morning .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<criteria>Age &gt; 18 h CRP &gt; 3mg/L &lt; 10 mg/L Active infection Systemic Inflammatory Disease Currently warfarin Cr &gt; 2.0 Fish Allergy Pregnancy unwillingness use form birth control</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Omega3 fatty acid</keyword>
	<keyword>hsCRP</keyword>
	<keyword>CAD</keyword>
</DOC>